MDA-19

MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. It has analgesic effects in animal studies, particularly against "atypical" pain types such as hyperalgesia and allodynia, and has also been shown to reduce the anxiety-like behaviour often associated with pain states.

Pharmacology

MDA-19 is a cannabinoid receptor agonist, meaning it activates the cannabinoid receptors in the body. It has a high affinity for the CB2 receptor, which is primarily found in the peripheral nervous system, immune cells, and gastrointestinal system. The CB2 receptor is involved in regulating immune system function and inflammation, and is the target of many medical cannabis treatments.

MDA-19 also has a lower affinity for the CB1 receptor, which is primarily found in the brain and central nervous system. Activation of the CB1 receptor is responsible for the psychoactive effects of cannabis. However, MDA-19 is selective for the CB2 receptor, meaning it does not produce significant psychoactive effects.

Medical Uses

In animal studies, MDA-19 has been shown to have analgesic effects, particularly against atypical pain types such as hyperalgesia and allodynia. Hyperalgesia is an increased sensitivity to pain, while allodynia is a condition where normally non-painful stimuli are perceived as painful.

MDA-19 has also been shown to reduce anxiety-like behaviour often associated with pain states. This suggests that it may have potential as a treatment for conditions involving chronic pain and anxiety.

See Also

• Cannabinoid receptor
• CB1
• CB2
• Cannabinoid
• Hyperalgesia
• Allodynia

MDA-19 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia